These proteins, called MDM2 and MDMX, become overactive in cancer and break down p53. Researchers have developed drugs to block MDM2 or MDMX, but targeting just one of these proteins is often not ...

Nevertheless, MdmX has been reported to migrate at M r 70–90K (depending on the method used), and upon in vitro translation it co-migrates with Mdm2 at M r ∼ 90K on SDS–polyacrylamide gels 9.

A Nigerian scientist, Prosper Chukwuemeka is combining data-driven insights with biological research to evolve a smarter and effective cancer treatment. Chukwuemeka’s research targets uncovering ...

However, loss of p53 tumour-suppressor activity can also occur through amplification of MDM2. As MDM2 is a negative regulator of p53, this promotes p53 degradation and inhibits p53 tumour ...

It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor ...